George Yancopoulos, Regeneron

2013 pay package: $31 million
2012 pay package: $81.6 million
Change: -62%
2013 compensation: $879,800 in salary; $1.8 million bonus; $28.1 million in option awards; and $281,455 in other compensation

George Yancopoulos, a member of FierceBiotech's 2014 list of the most influential people in biopharma, took a considerable cut in total compensation last year. But the 20-year Regeneron ($REGN) veteran is still the industry's top-paid scientist, and the colossal stock award that inflated his 2012 total is likely only to increase in value.

Not accounting for a 500,000-share bonus handed out in 2012, Yancopoulos' compensation increased by about 30% last year thanks to a step increase in salary and a 31% jump in option awards. And the gift of Yancopoulos' lucrative 2012 isn't quite done giving: That 500,000-share restricted stock award vests in 2017, and while its value was estimated at $57.3 million in 2012, it's worth nearly three times that at Regeneron's current share price.

Yancopoulos' pay comes as little surprise considering his recent résumé, which includes FDA approvals for the in-house candidates that became Zaltrap, Arcalyst and Eylea, the latter of which took a quick trip to blockbuster territory after its launch in 2011.

And Yancopoulos's best--or at least most valuable--work may still be ahead of him. Regeneron and partner Sanofi ($SNY) are racing through Phase III studies with alirocumab, a PCSK9-blocking cholesterol drug that has the chance to lead a $10 billion market. And the company has re-upped with Eylea co-developer Bayer to get working on a new drug that could work in combination with the billion-dollar wet age-related macular degeneration therapy.

- read the proxy statement

For more:
Special Report:
2014's most influential people in biopharma - George Yancopoulos
Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal
Regeneron R&D chief's compensation shrinks, but still tops the chart
How Regeneron's Yancopoulos became the top-paid executive in biotech

George Yancopoulos, Regeneron

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.